Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) on behalf of investors who purchased shares of the Company’s stock between February 14, 2020 and March 9, 2020, inclusive (the "Class Period").
Inovio investors are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 – 1740, or by email at email@example.com, for additional information about this action and their legal rights and options. Additional information may also be found at http://kaskelalaw.com/case/inovio/.
The shareholder class action lawsuit alleges that Inovio made a series of misleading statements to investors about the Company’s development of a purported vaccine for the novel coronavirus, which artificially inflated the value of the Company’s shares during the Class Period and resulted in significant investor losses.
IMPORTANT DEADLINE: Investors who purchased Inovio’s securities during the Class Period may, no later than May 12, 2020, seek to be appointed as a lead plaintiff shareholders representative in the action.
To discuss this action please contact Kaskela Law LLC. Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.